Last reviewed · How we verify

Placebo to bevacizumab

Hoffmann-La Roche · Phase 3 active Small molecule

Placebo to bevacizumab is a VEGF inhibitor Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 3 development for Metastatic colorectal cancer, Non-small cell lung cancer, Breast cancer.

Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.

Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Breast cancer.

At a glance

Generic namePlacebo to bevacizumab
SponsorHoffmann-La Roche
Drug classVEGF inhibitor
TargetVEGF-A
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Bevacizumab binds to VEGF-A with high affinity, preventing it from binding to its receptor on the surface of endothelial cells. This inhibits the formation of new blood vessels, which is a key process in tumor growth and metastasis. By inhibiting angiogenesis, bevacizumab can slow or stop the growth of certain types of cancer.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo to bevacizumab

What is Placebo to bevacizumab?

Placebo to bevacizumab is a VEGF inhibitor drug developed by Hoffmann-La Roche, indicated for Metastatic colorectal cancer, Non-small cell lung cancer, Breast cancer.

How does Placebo to bevacizumab work?

Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.

What is Placebo to bevacizumab used for?

Placebo to bevacizumab is indicated for Metastatic colorectal cancer, Non-small cell lung cancer, Breast cancer, Glioblastoma, Renal cell carcinoma.

Who makes Placebo to bevacizumab?

Placebo to bevacizumab is developed by Hoffmann-La Roche (see full Hoffmann-La Roche pipeline at /company/roche).

What drug class is Placebo to bevacizumab in?

Placebo to bevacizumab belongs to the VEGF inhibitor class. See all VEGF inhibitor drugs at /class/vegf-inhibitor.

What development phase is Placebo to bevacizumab in?

Placebo to bevacizumab is in Phase 3.

What are the side effects of Placebo to bevacizumab?

Common side effects of Placebo to bevacizumab include Hypertension, Nausea, Fatigue, Headache, Rash.

What does Placebo to bevacizumab target?

Placebo to bevacizumab targets VEGF-A and is a VEGF inhibitor.

Related